Developing next-generation biological drugs for treating wounds in skin and mucosa


Ilya Pharma, an innovative Swedish startup, develops drug candidates for PoC in Phase I and II trials from its library of lactic acid bacteria expressing human effector proteins.



Human therapeutic proteins are delivered on site in wounds by living lactic acid bacteria acting like small bioreactors. This is a very cost-effective way to deliver biological drugs.

We have a freeze-dried formulation with good stability. The lactic acid bacteria are revived immediately prior use by addition of a small volume of water.



The innovation stems from world-leading medical research in immunophysiology and microbiology at Uppsala University and the Swedish University of Agricultural Sciences. The treatments target the function of tissue-resident immune cells and the mechanism of accelerated healing is known.



The unmet clinical need targeted by Ilya Pharma is post-operative and chronic wounds, which are especially problematic for people with diabetes. Indications in the gastrointestinal tract such as irritable bowel disease (IBD) are also targeted.

There is much room for improvement in wound care and the innovative technology of Ilya Pharma offers is more efficient and very cost effective compared to treatment with conventional biological drugs, expected to enter the wound care market.


Contact Us

Evelina Vågesjö, CEO
Ilya Pharma, Uppsala, Sweden

tvv swelife